Cholesterol-lowering therapy: Old evidence, new guidelines--Which one to follow? A critical appraisal

Area of Science:

• Cardiology
• Atherosclerosis Research
• Evidence-Based Medicine

Background:

• Major cardiology and atherosclerosis societies (ESC/EAS, ACC/AHA, IAS) offer differing lipid-lowering therapy recommendations.
• Current guidelines are based on the same evidence but yield divergent conclusions.
• A strict evidence-based approach may neglect certain lipid disorders lacking randomized trial data.

Purpose of the Study:

• To analyze discrepancies in lipid-lowering therapy guidelines from prominent international societies.
• To highlight the clinical gap created by differing guideline approaches.
• To introduce the International Atherosclerosis Society's innovative concept for cholesterol management.

Main Methods:

• Comparative analysis of current European Society of Cardiology/European Atherosclerosis Society (ESC/EAS), American College of Cardiology/American Heart Association (ACC/AHA), and International Atherosclerosis Society (IAS) guidelines.
• Evaluation of the evidence base underpinning each guideline's recommendations.
• Assessment of the scope of lipid disorder coverage within each guideline set.

Main Results:

• ESC/EAS guidelines categorize treatments for specific lipid disorders.
• ACC/AHA guidelines prioritize statin trial evidence, omitting recommendations for lipid disorders without such data.
• The IAS proposes a novel, unified cholesterol target applicable to all individuals, contrasting with other guidelines.

Conclusions:

• Discrepancies in lipid-lowering guidelines present challenges for clinical practice.
• A strict adherence to evidence from randomized trials may result in significant gaps in patient care.
• The IAS's proposed universal cholesterol goal represents a paradigm shift in evidence-based lipid management.